{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-008965","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2023-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.460038+00:00","generated_at":"2026-06-19T23:03:18.353932+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Unicycive receives Nasdaq delisting notice for bid price non-compliance; equity below $5M","bullets":["On Feb 1, 2023, Nasdaq notified Unicycive (UNCY) that it failed to regain minimum bid price compliance by Jan 30 deadline.","Company not eligible for second 180-day grace period because stockholders' equity of $4.626M was below $5M initial listing requirement.","Unicycive requested a hearing before the Nasdaq Hearings Panel, scheduled for March 23, 2023, to stay delisting.","If Panel grants extension, company may have until August 8, 2023 to cure bid-price deficiency.","Common stock continues trading on Nasdaq under symbol UNCY pending hearing outcome."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-008965","json":"https://secwatch.observer/filing/0001213900-23-008965.json","markdown":"https://secwatch.observer/filing/0001213900-23-008965.md","text":"https://secwatch.observer/filing/0001213900-23-008965.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023008965/0001213900-23-008965-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023008965/ea172745-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T23:03:18.353932+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e522fe4d2f30b12faa7f398f3b64a2cffefd09a","claim":"Unicycive Therapeutics, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"February 1, 2023, Nasdaq notified the Company that it had not regained compliance with the Rule and was not eligible for a second 180 day period since the Company did not comply with the minimum $5,000,000 stockholders’ equity initial listing requirement for The Nasdaq Capital Market. In that regard, the Company’s stockholders’ equity as of September 30, 2022 was reported to be approximately $4,626,000, in the Company’s Form 10-Q filed on November 14, 2022. Further, the Staff informed the Company that its common stock would be subject to delisting from The Nasdaq Capital Market unless the Comp","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023008965/0001213900-23-008965-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"fda03c1d1db17a84a5fb6f56ce1fecd5ce20f6a8","claim":"Unicycive Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"February 1, 2023, Nasdaq notified the Company that it had not regained compliance with the Rule and was not eligible for a second 180 day period since the Company did not comply with the minimum $5,000,000 stockholders’ equity initial listing requirement for The Nasdaq Capital Market. In that regard, the Company’s stockholders’ equity as of September 30, 2022 was reported to be approximately $4,626,000, in the Company’s Form 10-Q filed on November 14, 2022. Further, the Staff informed the Company that its common stock would be subject to delisting from The Nasdaq Capital Market unless the Comp","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390023008965/0001213900-23-008965-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}